StockData
Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$8.92−0.40 (-4.29%)

Close on Nov 17, 2026Market cap $147.90MP/E –Yield –

Sutro Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sutro Biopharma's free cash flow for the twelve months ending Sep 30, 2019 was -$60.03M, down 585.6% year over year. For fiscal 2018 it was $11.13M.

Annual free cash flow

PeriodPeriod endValueChange
FY2018Dec 31, 2018$11.13M–
FY2017Dec 31, 2017-$40.39M–
FY2016Dec 31, 2016-$17.55M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020-$19.50M–
Q3 FY2019Sep 30, 2019-$16.79M-135.6%
Q2 FY2019Jun 30, 2019-$16.09M–
Q1 FY2019Mar 31, 2019-$20.42M–
Q4 FY2018Dec 31, 2018-$6.73M–
Q3 FY2018Sep 30, 2018$47.21M–
Q2 FY2018Jun 30, 2018-$13.98M–
Q1 FY2018Mar 31, 2018-$15.37M–
Q4 FY2017Dec 31, 2017-$5.50M–

More Sutro Biopharma figures

See a number that looks wrong?